Recent clinical trials exhibit a breakthrough in antibody-drug conjugates (ADCs) for oncological care, particularly for non-small cell lung cancer (NSCLC) and HER2-positive breast cancer. The bispecific ADC iza-bren, combined with osimertinib, demonstrated a 100% objective response rate in EGFR-mutated NSCLC in Phase II trials, underscoring potent antitumor activity. Concurrently, the CheckMate 77T Phase 3 trial affirmed that perioperative nivolumab preserves quality of life in resectable NSCLC patients, supporting immunotherapy integration. Furthermore, BioNTech and Duality Biologics reported that their HER2-targeting ADC, trastuzumab pamirtecan, surpassed Roche’s Kadcyla in progression-free survival during a Phase 3 trial in China, signifying a potential new standard for HER2-positive breast cancer treatment. These data collectively spotlight ADCs as pivotal agents reshaping cancer therapy trajectories.